Classic Kaposi Sarcoma malady

Rare diseases, Cancer diseases categories

Aliases & Classifications for Classic Kaposi Sarcoma

About this section

Aliases & Descriptions for Classic Kaposi Sarcoma:

Name: Classic Kaposi Sarcoma 42
Kaposis Sarcoma 42 10
Hhv8 42 37
Non-Aids-Related Kaposi Sarcoma 61
Non Aids Related Kaposi Sarcoma 42
Mediterranean Kaposi Sarcoma 42
Kaposi Sarcoma Herpesvirus 42
Classic Kaposi's Sarcoma 61
Human Herpesvirus 8 42
Kaposi's Sarcoma 42
Kaposi Sarcoma 61
Kshv 42


Summaries for Classic Kaposi Sarcoma

About this section
MalaCards based summary: Classic Kaposi Sarcoma, also known as kaposis sarcoma, is related to aids dementia complex and gingivitis. An important gene associated with Classic Kaposi Sarcoma is STIM1 (stromal interaction molecule 1), and among its related pathways are TRAF Pathway and OX40 Pathway. The drugs etoposide and interferon alfa-2a and the compounds oxazolone and as 101 have been mentioned in the context of this disorder. Affiliated tissues include t cells and lymph node, and related mouse phenotypes are digestive/alimentary and integument.

Related Diseases for Classic Kaposi Sarcoma

About this section

Diseases related to Classic Kaposi Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 182)
idRelated DiseaseScoreTop Affiliating Genes
1aids dementia complex30.7IL1B, TNF
2gingivitis30.6IL1B, IL1A
3dermatitis30.5IL4, IL13
4common variable immunodeficiency30.5IL10, IL4
5hepatitis c30.3IL10, IL4, TNF
6systemic lupus erythematosus30.1TNF, FCGR3A, IL4, IL10
7malaria30.1IL1A, IL1B, IL10, TNF
8leukemia30.0IL1A, IL1B, IL4, CCND1, TNF
9synovitis29.9IL1A, IL1B, IL8, TNF
10tuberculosis29.8TNF, CXCR2, IL4, IL10, IL1B
11myeloma29.8IL1B, IL4, CCND1
12arthritis29.6IL1A, IL1B, IL8, TNF
13pneumonia29.3TNF, CXCR2, IL10, IL8, IL1B, IL13
14colitis29.0TNF, IL4, IL10, IL8, IL1B, IL13
15atopic dermatitis29.0TNF, FCGR3A, IL4, IL10, IL8, IL13
16ulcerative colitis28.6TNF, CXCR2, IL4, IL10, IL8, IL1B
17rheumatoid arthritis28.4TNF, FCGR3A, CXCR2, IL4, IL10, IL8
18kaposi sarcoma11.1
20endemic kaposi sarcoma10.7
24periapical granuloma10.5IL4
25periodontal disease10.4TNF
26intervertebral disc disease10.4IL1B
27intraocular lymphoma10.4IL10
28colon kaposi sarcoma10.4
29muckle-wells syndrome10.4IL1B
30pulmonary hypertension10.3
31mycosis fungoides10.3
34poems syndrome10.3
36plasma cell leukemia10.3
37hodgkin lymphoma10.3
38secondary syphilis10.3
40primary effusion lymphoma10.3
41allergic conjunctivitis10.3IL4, IL13
42kshv inflammatory cytokine syndrome10.3
43asthma10.3IL13, IL4
44allergic rhinitis10.3IL13, IL4
45food allergy10.3IL4, IL13
46skin disease10.2IL1A, IL1B
49membranous glomerulonephritis10.2
50rectum kaposi's sarcoma10.2

Graphical network of the top 20 diseases related to Classic Kaposi Sarcoma:

Diseases related to classic kaposi sarcoma

Symptoms for Classic Kaposi Sarcoma

About this section

Drugs & Therapeutics for Classic Kaposi Sarcoma

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)13 Pharmaceutical Company Approval Date
Doxil13 38 DOXORUBICIN HYDROCHLORIDE Alza Approved June 1999
FDA Label: Doxil
Malady that Drug Treats: ovarian cancer that is refractory to other first-line therapies
Indications and Usage:13 DOXIL is an anthracycline topoisomerase II inhibitor indicated for:; Ovarian cancer (1.1); After failure of platinum-based chemotherapy.; AIDS-related Kaposi s Sarcoma (1.2); After failure of prior systemic chemotherapy or intolerance to such therapy.; Multiple Myeloma (1.3); In combination with bortezomib in patients who have not previously; received bortezomib and have received at least one prior therapy.
DrugBank Targets:11 1. DNA; 2. DNA topoisomerase 2-alpha
Mechanism of Action:13 
Target: nucleic acid; synthesis
Action: inhibitor
FDA: The active ingredient of DOXIL is doxorubicin HCl. The mechanism of action of; doxorubicin HCl is thought to be related to its ability to bind DNA and inhibit nucleic acid; synthesis. Cell structure studies have demonstrated rapid cell penetration and perinuclear; Reference ID: 3733596; 17 ; ; ; ; ; chromatin binding, rapid inhibition of mitotic activity and nucleic acid synthesis, and; induction of mutagenesis and chromosomal aberrations.
Intron A13 38 INTERFERON ALFA-2B Schering-Plough Approved December 1997/ Approved December 1995/ Approved March 1997
FDA Label: Intron A
Malady that Drug Treats: non-Hodgkin's lymphoma/ malignant melanoma / Hepatitis C
Indications and Usage:13 Hairy Cell Leukemia INTRON® A is indicated for the treatment of patients 18 years of; age or older with hairy cell leukemia.; Malignant Melanoma INTRON A is indicated as adjuvant to surgical treatment in; patients 18 years of age or older with malignant melanoma who are free of disease but; at high risk for systemic recurrence, within 56 days of surgery.; Follicular Lymphoma INTRON A is indicated for the initial treatment of clinically; aggressive (see Clinical Pharmacology) follicular Non-Hodgkin s Lymphoma in; conjunction with anthracycline-containing combination chemotherapy in patients 18; years of age or older. Efficacy of INTRON A therapy in patients with low-grade, lowtumor; burden follicular Non-Hodgkin s Lymphoma has not been demonstrated.; Condylomata Acuminata INTRON A is indicated for intralesional treatment of selected; patients 18 years of age or older with condylomata acuminata involving external; surfaces of the genital and perianal areas (see DOSAGE AND ADMINISTRATION).; The use of this product in adolescents has not been studied.; AIDS-Related Kaposi's Sarcoma INTRON A is indicated for the treatment of selected; patients 18 years of age or older with AIDS-Related Kaposi's Sarcoma. The likelihood; of response to INTRON A therapy is greater in patients who are without systemic symptoms, who have limited lymphadenopathy and who have a relatively intact immune; system as indicated by total CD4 count.; Chronic Hepatitis C INTRON A is indicated for the treatment of chronic hepatitis C in; patients 18 years of age or older with compensated liver disease who have a history of; blood or blood-product exposure and/or are HCV antibody positive. Studies in these; patients demonstrated that INTRON A therapy can produce clinically meaningful effects; on this disease, manifested by normalization of serum alanine aminotransferase (ALT); and reduction in liver necrosis and degeneration.; A liver biopsy should be performed to establish the diagnosis of chronic hepatitis.; Patients should be tested for the presence of antibody to HCV. Patients with other; causes of chronic hepatitis, including autoimmune hepatitis, should be excluded. Prior; to initiation of INTRON A therapy, the physician should establish that the patient has; compensated liver disease. The following patient entrance criteria for compensated liver; disease were used in the clinical studies and should be considered before INTRON A; treatment of patients with chronic hepatitis C:; No history of hepatic encephalopathy, variceal bleeding, ascites, or other; clinical signs of decompensation; Bilirubin Less than or equal to 2 mg/dL; Albumin Stable and within normal limits; Prothrombin Time Less than 3 seconds prolonged; WBC Greater than or equal to 3000/mm3; Platelets Greater than or equal to 70,000/mm3; Serum creatinine should be normal or near normal.; Prior to initiation of INTRON A therapy, CBC and platelet counts should be; evaluated in order to establish baselines for monitoring potential toxicity. These tests; should be repeated at Weeks 1 and 2 following initiation of INTRON A therapy, and; monthly thereafter. Serum ALT should be evaluated at approximately 3-month intervals; to assess response to treatment (see DOSAGE AND ADMINISTRATION).; Patients with preexisting thyroid abnormalities may be treated if thyroidstimulating; hormone (TSH) levels can be maintained in the normal range by medication.; TSH levels must be within normal limits upon initiation of INTRON A treatment and TSH; testing should be repeated at 3 and 6 months (see PRECAUTIONS, Laboratory; Tests).; INTRON A in combination with REBETOL® is indicated for the treatment of; chronic hepatitis C in patients 3 years of age and older with compensated liver disease; previously untreated with alpha interferon therapy and in patients 18 years of age and; older who have relapsed following alpha interferon therapy. See REBETOL prescribing; information for additional information. Chronic Hepatitis B INTRON A is indicated for the treatment of chronic hepatitis B in; patients 1 year of age or older with compensated liver disease. Patients who have been; serum HBsAg positive for at least 6 months and have evidence of HBV replication; (serum HBeAg positive) with elevated serum ALT are candidates for treatment. Studies; in these patients demonstrated that INTRON A therapy can produce virologic remission; of this disease (loss of serum HBeAg) and normalization of serum aminotransferases.; INTRON A therapy resulted in the loss of serum HBsAg in some responding patients.; Prior to initiation of INTRON A therapy, it is recommended that a liver biopsy be; performed to establish the presence of chronic hepatitis and the extent of liver damage.; The physician should establish that the patient has compensated liver disease. The; following patient entrance criteria for compensated liver disease were used in the; clinical studies and should be considered before INTRON A treatment of patients with; chronic hepatitis B:; No history of hepatic encephalopathy, variceal bleeding, ascites, or other; signs of clinical decompensation; Bilirubin Normal; Albumin Stable and within normal limits; Prothrombin Time Adults less than 3 seconds prolonged; Pediatrics less than or equal to 2 seconds prolonged; WBC Greater than or equal to 4000/mm3; Platelets Adults greater than or equal to 100,000/mm3; Pediatrics greater than or equal to 150,000/mm3; Patients with causes of chronic hepatitis other than chronic hepatitis B or chronic; hepatitis C should not be treated with INTRON A. CBC and platelet counts should be; evaluated prior to initiation of INTRON A therapy in order to establish baselines for; monitoring potential toxicity. These tests should be repeated at treatment Weeks 1, 2,; 4, 8, 12, and 16. Liver function tests, including serum ALT, albumin, and bilirubin,; should be evaluated at treatment Weeks 1, 2, 4, 8, 12, and 16. HBeAg, HBsAg, and; ALT should be evaluated at the end of therapy, as well as 3- and 6-months posttherapy,; since patients may become virologic responders during the 6-month period; following the end of treatment. In clinical studies in adults, 39% (15/38) of responding; patients lost HBeAg 1 to 6 months following the end of INTRON A therapy. Of; responding patients who lost HBsAg, 58% (7/12) did so 1 to 6 months post-treatment.; A transient increase in ALT greater than or equal to 2 times baseline value (flare); can occur during INTRON A therapy for chronic hepatitis B. In clinical trials in adults; and pediatrics, this flare generally occurred 8 to 12 weeks after initiation of therapy and; was more frequent in responders (adults 63%, 24/38; pediatrics 59%, 10/17) than in; nonresponders (adults 27%, 13/48; pediatrics 35%, 19/55). However, in adults and; pediatrics, elevations in bilirubin greater than or equal to 3 mg/dL (greater than or equal; to 2 times ULN) occurred infrequently (adults 2%, 2/86; pediatrics 3%, 2/72) during; therapy. When ALT flare occurs, in general, INTRON A therapy should be continued unless signs and symptoms of liver failure are observed. During ALT flare, clinical; symptomatology and liver function tests including ALT, prothrombin time, alkaline; phosphatase, albumin, and bilirubin, should be monitored at approximately 2-week; intervals (see WARNINGS).
DrugBank Targets:11 1. Interferon alpha/beta receptor 2; 2. Interferon alpha/beta receptor 1
Mechanism of Action:13 
Target: intracellular oncogene expression, natural killer and cytotoxic T-cells, microphage, cytokine production
Action: stimulation, induction (unspecified effects on oncogene expression)
FDA: -
Taxol13 38 PACLITAXEL Bristol-Myers Squibb Approved August 1997
FDA Label: Taxol
Malady that Drug Treats: Kaposi's Sarcoma
Indications and Usage:13 Paclitaxel Injection, USP is indicated as subsequent therapy for the treatment of advanced carcinoma of; the ovary. As first-line therapy, Paclitaxel Injection, USP is indicated in combination with cisplatin.; Paclitaxel Injection, USP is indicated for the adjuvant treatment of node-positive breast cancer; administered sequentially to standard doxorubicin-containing combination chemotherapy.. In the clinical; trial, there was an overall favorable effect on disease-free and overall survival in the total population of; patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and; progesterone receptor-negative tumors (see CLINICAL STUDIES, Breast Carcinoma).; Paclitaxel Injection, USP is indicated for the treatment of breast cancer after failure of combination; chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy; should have included an anthracycline unless clinically contraindicated.; Paclitaxel Injection, USP, in combination with cisplatin, is indicated for the first-line treatment of nonsmall; cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation; therapy.; Paclitaxel Injection, USP is indicated for the second-line treatment of AIDS-related Kaposi s sarcoma.
DrugBank Targets:11 1. Apoptosis regulator Bcl-2; 2. Tubulin beta-1 chain; 3. Nuclear receptor subfamily 1 group I member 2; 4. Microtubule-associated protein 4; 5. Microtubule-associated protein 2; 6. Microtubule-associated protein tau
Mechanism of Action:13 
Target: microtubules
Action: promoter of assembly & preventor of depolymerization
FDA: Paclitaxel is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin; dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition; of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and; mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or  bundles of microtubules; throughout the cell cycle and multiple asters of microtubules during mitosis.; Following intravenous administration of paclitaxel, paclitaxel plasma concentrations declined in a; biphasic manner. The initial rapid decline represents distribution to the peripheral compartment and; elimination of the drug. The later phase is due, in part, to a relatively slow efflux of paclitaxel from the; peripheral compartment.; Pharmacokinetic parameters of paclitaxel following 3- and 24-hour infusions of paclitaxel at dose levels; of 135 and 175 mg/m2; were determined in a Phase 3 randomized study in ovarian cancer patients and are; summarized in the following table:

Drug clinical trials:

Search ClinicalTrials for Classic Kaposi Sarcoma

Search NIH Clinical Center for Classic Kaposi Sarcoma

Inferred drug relations via UMLS61/NDF-RT40:

Genetic Tests for Classic Kaposi Sarcoma

About this section

Anatomical Context for Classic Kaposi Sarcoma

About this section

MalaCards organs/tissues related to Classic Kaposi Sarcoma:

T cells, Lymph node

Animal Models for Classic Kaposi Sarcoma or affiliated genes

About this section

Publications for Classic Kaposi Sarcoma

About this section

Articles related to Classic Kaposi Sarcoma:

(show top 50)    (show all 55)
Classic Kaposi Sarcoma: to treat or not to treat? (25889316)
From the lymph nodes to the muscles: an unusual case of refractory familial Mediterranean classic Kaposi sarcoma. (24739057)
Whole-Genome Sequencing Identifies STAT4 as a Putative Susceptibility Gene in Classic Kaposi Sarcoma. (25492914)
Treatments for classic Kaposi sarcoma: a systematic review of the literature. (22695100)
Familial classic Kaposi sarcoma in two siblings: case report and literature review. (24067858)
Inherited human OX40 deficiency underlying classic Kaposi sarcoma of childhood. (23897980)
Classic kaposi sarcoma with pulmonary involvement mimicking endobronchial tuberculosis in a child. (22825845)
Efficacy of 5% imiquimod cream in a patient with classic Kaposi sarcoma. (22826720)
Variable clinical presentations of Classic Kaposi Sarcoma in Turkish patients. (22514583)
Delayed-type hypersensitivity in classic Kaposi sarcoma patients and controls. (21245864)
Classic Kaposi sarcoma. (21788419)
Pilot study of oral valganciclovir therapy in patients with classic Kaposi sarcoma. (21450998)
Prevalence of toscana and sicilian phlebovirus antibodies in classic Kaposi sarcoma case patients and control subjects in sicily. (21900487)
AIDS-Kaposi Sarcoma and Classic Kaposi Sarcoma: are different ultrasound patterns related to different variants? (21489270)
Proximal Subungual Onychomycosis in a Patient with Classic Kaposi Sarcoma Caused by Trichophyton rubrum. (22028554)
Classic Kaposi sarcoma mimicking chilblains. (21382299)
Successful treatment of classic Kaposi sarcoma with low-dose intramuscular immunoglobulins. (21166659)
Case of classic Kaposi sarcoma. (23847803)
A case of classic Kaposi sarcoma in a 11-year-old male. (22016293)
Differences in Kaposi sarcoma-associated herpesvirus-specific and herpesvirus-non-specific immune responses in classic Kaposi sarcoma cases and matched controls in Sicily. (21740480)
Risk of classic Kaposi sarcoma with exposures to plants and soils in Sicily. (21126363)
Whole-exome sequencing-based discovery of STIM1 deficiency in a child with fatal classic Kaposi sarcoma. (20876309)
Classic Kaposi sarcoma in 3 unrelated Turkish children born to consanguineous kindreds. (20156905)
Intralesional vincristine as first-line therapy for nodular lesions in classic Kaposi sarcoma: a prospective study in 151 patients. (19995366)
Results of radiation therapy for treatment of classic Kaposi sarcoma. (19298767)
Risk of classic Kaposi sarcoma with residential exposure to volcanic and related soils in Sicily. (19576540)
Classic Kaposi sarcoma with sarcoid-like granulomas: a case report and literature review. (19679122)
Classic Kaposi sarcoma treated with intralesional 5-aminolevulinic acid injection photodynamic therapy. (19841419)
Pegylated liposomal doxorubicin as second-line therapy in the treatment of patients with advanced classic Kaposi sarcoma: a retrospective study. (18098221)
Treatment of classic Kaposi sarcoma with a nicotine dermal patch: a phase II clinical trial. (18384551)
Weekly paclitaxel for advanced aggressive classic Kaposi sarcoma: experience in 17 cases. (18363766)
Low to moderate cumulative doses of pegylated liposomal doxorubicin in the treatment of classic Kaposi sarcoma in elderly patients with comorbidities. (18067475)
Classic Kaposi Sarcoma in the United States over the last two decades: a clinicopathologic and molecular study of 438 non-HIV-related Kaposi Sarcoma patients with comparison to HIV-related Kaposi Sarcoma. (18376387)
Relationship between human herpesvirus 8 loads and disease stage in classic Kaposi sarcoma patients. (17403447)
Rapidly progressive classic Kaposi sarcoma in an adolescent: response to interferon alfa therapy and biological correlates. (16445793)
Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma. (16991082)
Failure of topical 0.1% alitretinoin gel for classic Kaposi sarcoma: first European experience. (16965450)
Virologic, hematologic, and immunologic risk factors for classic Kaposi sarcoma. (16998933)
Environmental factors influence the rate of human herpesvirus type 8 infection in a population with high incidence of classic Kaposi sarcoma. (16511749)
Associations of classic Kaposi sarcoma with common variants in genes that modulate host immunity. (16702372)
Classic Kaposi sarcoma in northern Sardinia: a prospective epidemiologic overview (1977-2003) correlated with malaria prevalence (1934). (17097396)
A common genetic variant in FCGR3A-V158F and risk of Kaposi sarcoma herpesvirus infection and classic Kaposi sarcoma. (15767342)
Cyclin D1 overexpression in AIDS-related and classic Kaposi sarcoma. (15163015)
Familial clustering of classic Kaposi sarcoma. (15143469)
Topical 0.1% alitretinoin gel for classic Kaposi sarcoma. (11939830)
Classic kaposi sarcoma: epidemiology and risk factors. (10649240)
Classic Kaposi sarcoma: experience at Rabin Medical Center in Israel. (9781608)
Recombinant interleukin 2 monotherapy for classic Kaposi sarcoma. (9801673)
Human herpesvirus 8 in classic Kaposi sarcoma. (9147730)
Intralesional treatment of classical Kaposi sarcoma with interferon-alpha]. (1361927)

Variations for Classic Kaposi Sarcoma

About this section

Expression for genes affiliated with Classic Kaposi Sarcoma

About this section
Search GEO for disease gene expression data for Classic Kaposi Sarcoma.

Pathways for genes affiliated with Classic Kaposi Sarcoma

About this section

Pathways related to Classic Kaposi Sarcoma according to GeneCards Suite gene sharing:

(show top 50)    (show all 64)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
Show member pathways
29.3IL4, IL10, IL13
Show member pathways
9.3IL1B, IL13, IL1A
Show member pathways
Immune response IL 12 induced IFN gamma production59
9.3IL4, IL12A, IL1B
59.2IL4, IL1B, IL13
69.1IL1B, TNF
79.1IL13, IL8, IL4
Show member pathways
9.0IL1A, IL1B, IL8
99.0IL8, IL1B, IL1A
Show member pathways
8.9IL10, IL12A, TNF
118.8IL1B, IL12A, TNF
128.8IL1A, IL1B, TNF
Show member pathways
8.8TNF, IL1B, IL1A
Show member pathways
8.7TNF, IL12A, IL8
Show member pathways
IL23-mediated signaling events36
Immune response IL 10 signaling pathway59
Angiopoietin receptor Tie2-mediated signaling36
Development PDGF signaling via STATs and NF kB59
Development Angiopoietin Tie2 signaling59
8.7IL1B, IL10, TNF
Show member pathways
Type III interferon signaling36
8.6IL13, IL10, IL12A, IL4, CCND1
Show member pathways
Calcium signaling in the CD4+ TCR pathway36
8.6TNF, IL4, IL8
Show member pathways
8.5IL1B, IL8, TNF
198.5IL1B, IL8, TNF
208.5IL1A, IL1B, FCGR3A, TNF
Show member pathways
IL27-mediated signaling events36
8.4TNF, IL12A, IL10, IL1B
228.4TNF, IL12A, IL10, IL1B
238.4IL1A, IL1B, IL4, TNF
248.2TNF, IL12A, IL8, IL1B
Show member pathways
8.2IL1A, IL1B, IL8, TNF
Show member pathways
Immune response Role of TLRs 3 and 4 in cell antiviral response TICAM1 specific signaling pathways59
Immune response IL 1 signaling pathway59
8.2TNF, IL8, IL1B, IL1A
Show member pathways
Immune response MIF in innate immunity response59
8.2IL1A, IL1B, IL8, TNF
288.2TNF, IL8, IL1B, IL1A
Show member pathways
8.0TNF, CCND1, IL4, IL1B, IL1A
308.0TNF, CCND1, IL10, IL1B, IL1A
Show member pathways
BCR signaling pathway36
TCR Signaling Pathway36
7.9TNF, IL4, IL10, IL1B, IL1A
327.8TNF, IL12A, IL10, IL8, IL1B
337.8IL1B, IL8, IL10, IL12A, TNF
Show member pathways
Transcription NF kB signaling pathway59
Immune response Toll like receptor TLR ligands and common TLR signaling pathway leading to cell proinflammatory response59
7.8TNF, IL4, IL8, IL1B, IL1A
357.7TNF, FCGR3A, IL12A, IL10, IL1B, IL1A
367.6IL1A, IL13, IL1B, IL10, IL4, TNF
377.4TNF, IL12A, IL10, IL8, IL1B, IL1A
Show member pathways
Toll-like receptor signaling pathway36
Regulation of toll-like receptor signaling pathway36
7.4TNF, CCND1, IL12A, IL10, IL8, IL1B
397.4TNF, IL10, IL8, IL1B, IL13, IL1A
407.4TNF, CCND1, IL4, IL8, IL1B, IL1A
Show member pathways
7.0IL1A, IL13, IL1B, IL10, IL12A, IL4
Show member pathways
6.9TNF, CCND1, IL4, IL12A, IL10, IL1B
Show member pathways
6.8TNF, CCND1, IL4, IL12A, IL8, IL1B
Show member pathways
6.7TNF, IL4, IL12A, IL10, IL8, IL1B
Show member pathways
6.7TNF, IL4, IL12A, IL10, IL8, IL1B
466.7IL12A, IL4, TNF, IL10, IL8, IL1B
Show member pathways
6.3TNF, CCND1, IL4, IL12A, IL10, IL8
Show member pathways
6.3TNF, CCND1, IL4, IL12A, IL10, IL8
Show member pathways
6.2TNF, CXCR2, IL4, IL12A, IL10, IL8

Compounds for genes affiliated with Classic Kaposi Sarcoma

About this section

Compounds related to Classic Kaposi Sarcoma according to GeneCards Suite gene sharing:

(show top 50)    (show all 183)
idCompoundScoreTop Affiliating Genes
1oxazolone449.6IL4, IL1A, IL13
2as 10144 6010.1IL10, IL1B, IL1A, IL13
3montelukast44 50 28 1111.9IL4, IL13, IL8, IL10
4gold sodium thiomalate448.5TNF, IL1A, IL8, IL1B
5imiquimod44 60 28 1111.4IL1A, IL8, IL10, TNF
6toxin-1448.4IL1B, TNF, IL10, IL8
75 aminosalicylic acid448.3IL10, IL8, IL1B, TNF
8ciglitazone44 289.2IL1B, IL8, CCND1, TNF
9rolipram44 60 2810.2IL4, TNF, IL13, IL8, IL10
10budesonide44 50 1110.2IL4, IL1B, IL8, TNF, IL13
11ns 39844 609.2IL1A, IL1B, TNF, IL8, CCND1
12fluticasone propionate44 50 60 1111.1IL4, IL1B, IL13, IL8, TNF
13etanercept44 50 1110.1IL1B, TNF, FCGR3A, IL8, IL10
14sp 60012544 609.1IL13, IL1B, IL8, CCND1, TNF
15pdtc448.0IL1A, TNF, IL4, IL8, IL1B
16ivig448.0IL1A, IL1B, TNF, FCGR3A, IL4, IL10
17thalidomide44 50 60 1111.0TNF, IL10, IL1B, IL13, IL1A, CCND1
18calcitriol44 60 24 1110.9TNF, IL4, IL10, IL1B, IL13, IL1A
19tarc447.9TNF, IL4, IL8, IL13, IL1A, IL10
20lipoteichoic acid447.9IL1B, CXCR2, TNF, IL10, IL8
21tgf beta1447.9IL1B, IL10, TNF, CCND1, IL13
22sulfasalazine28 44 50 1110.9IL1B, IL1A, IL8, TNF
23simvastatin44 50 60 28 24 1112.8IL1A, IL8, IL10, TNF, IL4
24ccl344 288.8TNF, IL1B, IL8, IL13, IL1A, IL10
25mg 13244 608.8CCND1, TNF, IL1B, IL1A, IL8
26il-12447.8TNF, IL4, IL10, IL8, IL13, IL1B
27mip 1alpha447.8TNF, IL4, IL1B, IL8, IL10, IL13
28polymyxin b447.7TNF, IL1A, IL1B, IL8, IL10, IL4
29polyinosinic-polycytidylic acid447.7IL8, IL10, TNF, IL1B, IL1A, IL4
30leukotriene b444 60 249.7IL13, TNF, CXCR2, IL8, IL1B, IL1A
31neopterin447.7TNF, IL4, IL10, IL1A, IL1B, IL8
3215-deoxy-delta-12,14-prostaglandin j2447.7IL10, IL8, IL1B, IL4, CCND1, TNF
33actinomycin d447.5IL4, IL8, IL1B, IL13, TNF, IL1A
34thymidine44 248.5TNF, IL1B, IL13, IL10, IL1A, CCND1
35histamine44 28 249.5IL13, IL4, IL10, IL8, IL1B, TNF
36gm-csf44 288.4IL1B, IL10, IL8, IL13, IL4, IL1A
37fmlp447.4TNF, FCGR3A, CXCR2, IL8, IL1B, IL1A
38pentoxifylline44 118.4TNF, IL4, IL10, IL8, IL1B, IL13
39il 10447.4IL8, TNF, IL4, IL10, IL1A, IL13
40hydrocortisone44 1 60 1110.4IL8, IL1A, IL1B, IL13, TNF, IL4
41herbimycin a44 608.4IL1B, CXCR2, IL8, IL1A, TNF, FCGR3A
42pge2447.3IL1A, IL13, IL1B, IL8, IL10, IL4
43groalpha447.3IL1A, IL13, IL1B, IL8, IL10, CXCR2
44ly294002447.3IL13, IL1B, IL8, IL10, TNF, IL4
45endotoxin447.3CXCR2, IL10, IL1B, IL13, IL1A, IL8
46dexamethasone44 50 28 1110.1IL1B, IL8, TNF, IL13, IL1A, IL4
47sb 20358044 608.0IL1A, IL10, IL8, IL1B, CCND1, IL13
48cycloheximide447.0TNF, IL1A, IL13, CCND1, IL4, IL10
49rantes446.9TNF, CXCR2, IL4, IL10, IL8, IL1B
50vegf446.5IL1B, IL8, IL13, CCND1, IL10, IL4

GO Terms for genes affiliated with Classic Kaposi Sarcoma

About this section

Cellular components related to Classic Kaposi Sarcoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1external side of plasma membraneGO:00098978.3TNF, FCGR3A, IL4, IL13
2extracellular regionGO:00055767.5IL1A, IL13, IL1B, IL8, FCGR3A, TNF
3extracellular spaceGO:00056156.6IL1A, TNF, IL4, IL12A, IL10, IL8

Biological processes related to Classic Kaposi Sarcoma according to GeneCards Suite gene sharing:

(show top 50)    (show all 58)
idNameGO IDScoreTop Affiliating Genes
1regulation of proton transportGO:001015510.1IL4, IL13
2positive regulation of T cell differentiationGO:004558210.1IL4, IL12A
3regulation of isotype switchingGO:004519110.0IL4, IL10
4fever generationGO:000166010.0IL1B, IL1A
5type 2 immune responseGO:004209210.0IL4, IL10
6positive regulation of MHC class II biosynthetic processGO:004534810.0IL4, IL10
7defense response to protozoanGO:004283210.0IL4, IL12A
8ectopic germ cell programmed cell deathGO:003523410.0IL1B, IL1A
9negative regulation of nitric oxide biosynthetic processGO:00450199.9IL10, IL4
10positive regulation of interleukin-2 biosynthetic processGO:00450869.9IL1A, IL1B
11response to molecule of bacterial originGO:00022379.7IL8, IL10
12response to ethanolGO:00454719.7IL13, IL4, CCND1
13positive regulation vascular endothelial growth factor productionGO:00105759.7IL1A, IL1B
14positive regulation of T cell proliferationGO:00421029.7IL4, IL12A, IL1B
15neutrophil activationGO:00421199.7CXCR2, IL8
16extrinsic apoptotic signaling pathway in absence of ligandGO:00971929.6IL4, IL1B, IL1A
17receptor biosynthetic processGO:00328009.6TNF, IL10
18negative regulation of cytokine secretion involved in immune responseGO:00027409.6TNF, IL10
19positive regulation of calcidiol 1-monooxygenase activityGO:00605599.6TNF, IL1B
20sequestering of triglycerideGO:00307309.5TNF, IL1B
21positive regulation of heterotypic cell-cell adhesionGO:00341169.5TNF, IL1B
22positive regulation of fever generationGO:00316229.5TNF, IL1B
23positive regulation of neutrophil chemotaxisGO:00900239.5IL8, CXCR2
24regulation of I-kappaB kinase/NF-kappaB signalingGO:00431229.5TNF, IL1B
25positive regulation of angiogenesisGO:00457669.4CXCR2, IL1B, IL1A
26negative regulation of growth of symbiont in hostGO:00441309.4IL10, TNF
27positive regulation of membrane protein ectodomain proteolysisGO:00510449.4IL1B, TNF
28negative regulation of lipid catabolic processGO:00509959.4IL1B, TNF
29positive regulation of cytokine secretionGO:00507159.3IL1A, IL10, TNF
30positive regulation of interferon-gamma productionGO:00327299.3TNF, IL12A, IL1B
31positive regulation of NF-kappaB import into nucleusGO:00423469.3IL1B, TNF
32negative regulation of interleukin-6 productionGO:00327159.3TNF, IL10
33embryonic digestive tract developmentGO:00485669.3TNF, IL8
34chemotaxisGO:00069359.2IL8, IL4, CXCR2
35neutrophil chemotaxisGO:00305939.2IL1B, IL8, CXCR2
36positive regulation of mitosisGO:00458409.2TNF, IL1B, IL1A
37negative regulation of extrinsic apoptotic signaling pathway in absence of ligandGO:020012409.2IL1A, IL1B, TNF
38positive regulation of chemokine biosynthetic processGO:00450809.2TNF, IL4, IL1B
39lipopolysaccharide-mediated signaling pathwayGO:00316639.1IL1B, TNF
40positive regulation of nitric oxide biosynthetic processGO:00454299.1IL1B, TNF
41positive regulation of protein phosphorylationGO:00019349.1IL1B, CCND1, TNF
42response to activityGO:00148239.1IL10, TNF
43protein kinase B signalingGO:00434918.8IL1B, TNF
44response to drugGO:00424938.8IL10, IL4, CCND1, TNF
45positive regulation of sequence-specific DNA binding transcription factor activityGO:00510918.7IL1B, IL10, IL4, TNF
46positive regulation of transcription, DNA-templatedGO:00458938.5TNF, IL4, IL10, IL1B
47negative regulation of cell proliferationGO:00082858.5TNF, IL8, IL1B, IL1A
48positive regulation of transcription from RNA polymerase II promoterGO:00459448.3TNF, IL4, IL10, IL1B, IL1A
49immune responseGO:00069558.1FCGR3A, IL4, IL12A, IL8, IL1B, IL13
50inflammatory responseGO:00069547.3IL1A, TNF, CXCR2, IL10, IL8, IL1B

Molecular functions related to Classic Kaposi Sarcoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1growth factor activityGO:00080839.3IL10, IL12A, IL4
2interleukin-1 receptor bindingGO:00051499.3IL1A, IL1B
3cytokine activityGO:00051257.3IL1A, TNF, IL4, IL12A, IL10, IL1B
4protein bindingGO:00055156.4TNF, CXCR2, STIM1, CCND1, IL4, IL12A

Sources for Classic Kaposi Sarcoma

About this section
26ICD10 via Orphanet
34MESH via Orphanet
47OMIM via Orphanet
57SNOMED-CT via Orphanet
62UMLS via Orphanet